Shape memory polymer intraocular lenses

1. An intraocular lens (IOL) comprising a shape memory polymer (SMP), wherein the SMP is derived from a formulation comprising:

50-85 wt % tert-butyl acrylate (tBA);

3-25 wt % of one or more poly(ethylene glycol) dimethacrylate (PEGDMA) monomers having a number average molecular weight (M n ) ranging from 500 g/mol to 2,000 g/mol; and

0.25-1.5 wt % of one or more UV-blockers;

the IOL having:

a refractive index above 1.45;

a Tg between 10° C. and 60° C., inclusive;

de minimis or an absence of glistening; and

substantially 100% transmissivity of light in the visible spectrum.

2. The IOL of claim 1 , wherein the formulation further comprises 0.05-3.0 wt % of one or more polymerization initiators.

3. The IOL of claim 1 , wherein the formulation further comprises n-butyl acrylate (nBA).

4. The IOL of claim 1 , wherein the formulation further comprises 2-hydroxy-3-phenoxypropyl acrylate (HPPA).

5. The IOL of claim 1 , wherein the formulation further comprises:

0.05-3.0 wt % of one or more polymerization initiators;

nBA; and

HPPA.

6. The IOL of claim 1 , wherein the PEGDMA is selected from the group consisting of:

PEGDMA 550;

PEGDMA 750;

PEGDMA 1000;

PEGDMA 2000; and

any combination thereof.

7. The IOL of claim 1 , wherein the PEGDMA is PEGDMA 750.

8. The IOL of claim 1 , wherein the PEGDMA is PEGDMA 1000.

9. The IOL of claim 1 , wherein the one or more UV-blockers are selected from the group consisting of:

a methacryloyl chlorobenzotriazole;

a methacryloyl methoxybenzotriazole;

a yellow dye; and

any combination thereof.

10. The IOL of claim 1 , wherein the UV-blocker is selected from the group consisting of:

2-methylacrylic acid 3-[3-tert-butyl-5-(5-chlorobenzotriazol-2-yl)-4-hydroxyphenyl]-propyl ester (UVB); and

2-(2-hydroxy-3-tert-butyl-5-vinylphenyl)-5-chloro-2H-benzotriazole (UVAM).

11. The IOL of claim 1 , wherein the UV-blocker is 3-(tert-butyl)-4-hydroxy-5-(5-methoxy-2H-benzo[d][1,2,3]triazol-2-yl)phenethyl methacrylate.

12. The IOL of claim 2 , wherein the one or more polymerization initiators are selected from the group consisting of:

2,2-dimethoxy-2-phenylacetophenone (Irgacure 651);

phenylbis(2,4,6-trimethylbenzoyl) phosphine oxide (Irgacure 819);

azobisisobutyronitrile (AIBN);

lauroyl peroxide;

di(4-tert-butylcyclohexyl) peroxydicarbonate (Perkadox 16);

camphorquinone;

diphenyl-(2,4,6-trimethylbenzoyl)-phosphine oxide (TPO); and

any combination thereof.

13. The IOL of claim 2 , wherein the polymerization initiator is lauroyl peroxide.

14. The IOL of claim 2 , wherein the polymerization initiator includes a photo initiator and a thermal initiator.

15. An intraocular lens (IOL) comprising a shape memory polymer (SMP), wherein the SMP is derived from a formulation selected from the group consisting of SMP208, SMP209, SMP210, SMP211, SMP212, SMP213, SMP214, SMP215, SMP218, SMP219, and SMP230b, wherein:

SMP208 comprises tBA (77.5%), UVB (0.5%), PEGDMA 1000 (22%), and IRGACURE819 (0.15%);

SMP209 comprises tBA (77.0%), UVB (1.0%), PEGDMA 1000 (22%), and IRGACURE819 (0.15%);

SMP210 comprises tBA (76.0%), UVB (2.0%), PEGDMA 1000 (22%), and IRGACURE819 (0.15%);

SMP211 comprises tBA (77.5%), UVAM (0.5%), PEGDMA 1000 (22%), and IRGACURE819 (0.15%);

SMP212 comprises tBA (77.0%), UVAM (1.0%), PEGDMA 1000 (22%), and IRGACURE819 (0.15%);

SMP213 comprises tBA (76.0%), UVAM (2.0%), PEGDMA 1000 (22%), and IRGACURE819 (0.15%);

SMP214 comprises tBA (77.3%), UVB (0.7%), PEGDMA 1000 (22%), and IRGACURE819 (0.15%);

SMP215 comprises tBA (77.45%), UVAM (0.55%), PEGDMA 1000 (22%), and IRGACURE819 (0.15%);

SMP218 comprises tBA (64.30%), nBA (13.0%), UVB (0.7%), PEGDMA 1000 (22%), and IRGACURE819 (0.15%);

SMP219 comprises tBA (64.45%), nBA (13.0%), UVAM (0.55%), PEGDMA 1000 (22%), and IRGACURE819 (0.15%); and

SMP230b comprises tBA (59.80%), nBA (12.00%), UVB (0.80%), PEGDMA 1000 (10%), lauroyl peroxide (0.15%), and HPPA (17.50%);

wherein UVB is 2-methylacrylic acid 3-(3-tert-butyl-5-(5-chlorobenzotriazol-2-yl)-4-hydroxyphenyl]-propyl ester, UVAM is 2-(2-hydroxy-3-tert-butyl-5-vinylphenyl)-5-chloro-2H-benzotriazole (UVAM), and IRGACURE819 is phenylbis(2,4,6-trimethylbenzoyl) phosphine oxide,

the IOL having:

a refractive index above 1.45;

a Tg between 10° C. and 60° C., inclusive:

de minimis or an absence of glistening; and

substantially 100% transmissivity of light in the visible spectrum.

16. The IOL of claim 5 , wherein the formulation comprises:

59.80 wt % tBA;

12.00 wt % nBA;

17.50 wt % HPPA;

0.70 wt % 2-methylacrylic acid 3-[3-tert-butyl-5-(5-chlorobenzotriazol-2-yl)-4-hydroxyphenyl]-propyl ester (UVB);

10 wt % PEGDMA 1000; and

0.15 wt % of a polymerization initiator, wherein the polymerization initiator is lauroyl peroxide.

17. A method of implanting an intraocular lens, comprising:

making an incision in a cornea or sclera less than 2 mm wide; and

inserting the intraocular lens according to claim 1 into the capsular bag through the incision;

wherein the intraocular lens is implanted in a compressed and deformed configuration.

18. A method of implanting an intraocular lens comprising:

making an incision in a cornea or sclera less than 2 mm wide; and

inserting the intraocular lens according to claim 1 into the ciliary sulcus through the incision;

wherein the intraocular lens is implanted in a compressed and deformed configuration.

19. A method of implanting an intraocular lens device comprising

making an incision into a cornea less than 2 mm wide to access the anterior chamber, and

inserting the intraocular lens according claim 1 into the anterior chamber through the incision;

wherein the intraocular lens device is implanted in a compressed and deformed configuration.

20. An intraocular lens (IOL) comprising a shape memory polymer (SMP), wherein the SMP is derived from a formulation comprising:

50-85 wt % tert-butyl acrylate (tBA);

3-25 wt % of one or more poly(ethylene glycol) dimethacrylate (PEGDMA) monomers having a number average molecular weight (M n ) ranging from 500 g/mol to 2,000 g/mol;

n-butyl acrylate (nBA); and

2-hydroxy-3-phenoxypropyl acrylate (HPPA),

the IOL having:

a refractive index above 1.45;

a Tg between 10° C. and 60° C., inclusive;

de minimis or an absence of glistening; and

substantially 100% transmissivity of light in the visible spectrum.

21. The IOL of claim 20 , wherein the formulation comprises about 5 wt %, about 10 wt %, about 15 wt %, or about 20 wt % nBA.

22. The IOL of claim 20 , wherein the formulation comprises about 5 wt %, about 10 wt %, about 15 wt %, about 20 wt %, or 15 wt % to 20 wt % HPPA.

23. The IOL of claim 20 , wherein the PEGDMA is selected from the group consisting of: PEGDMA 550;

PEGDMA 750;

PEGDMA 1000;

PEGDMA 2000; and

any combination thereof.

24. The IOL of claim 20 , wherein the PEGDMA is PEGDMA 750.

25. The IOL of claim 20 , wherein the PEGDMA is PEGDMA 1000.

26. A method of implanting an intraocular lens, comprising:

making an incision in a cornea or sclera less than 2 mm wide; and

inserting the intraocular lens according to claim 20 into the capsular bag through the incision;

wherein the intraocular lens is implanted in a compressed and deformed configuration.

27. A method of implanting an intraocular lens comprising:

making an incision in a cornea or sclera less than 2 mm wide; and

inserting the intraocular lens according to claim 20 into the ciliary sulcus through the incision;

wherein the intraocular lens is implanted in a compressed and deformed configuration.

28. A method of implanting an intraocular lens device comprising:

making an incision into a cornea less than 2 mm wide to access the anterior chamber, and

inserting the intraocular lens according claim 20 into the anterior chamber through the incision;

wherein the intraocular lens device is implanted in a compressed and deformed configuration.